Referencia número: HY-13301

MPC-3100

Revisión del cliente

Based on 1 Customer Validation

MPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of Hsp90 with potential antineoplastic activity.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 98.4%
No. CAS: 958025-66-6
Fòrmula: C₂₂H₂₅BrN₆O₄S
Peso molecular:549.44

Almacenamiento:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

MPC-3100 Chemical Structure

No. CAS: 958025-66-6

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- Cellular Effect
- Ensayo clínico
Chemical Information
Solvente y solubilidad
- In Vitro
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

MPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of Hsp90 with potential antineoplastic activity^[1].

Ver todos los productos específicos de isoformas HSP :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.77 μM Compound: 28g, MPC-3100	Cytotoxicity against human A549 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human A549 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
BT-474	IC₅₀	0.55 μM Compound: 28g, MPC-3100	Cytotoxicity against human BT474 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human BT474 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
DU-145	IC₅₀	0.1 μM Compound: 28g, MPC-3100	Inhibition of human HSP90 in DU145 cells assessed as degradation of Akt incubated for 24 hrs by Western blot method Inhibition of human HSP90 in DU145 cells assessed as degradation of Akt incubated for 24 hrs by Western blot method	[PMID: 22913511]
DU-145	IC₅₀	0.1 μM Compound: 28g, MPC-3100	Inhibition of human HSP90 in DU145 cells assessed as degradation of Her2 incubated for 24 hrs by Western blot method Inhibition of human HSP90 in DU145 cells assessed as degradation of Her2 incubated for 24 hrs by Western blot method	[PMID: 22913511]
DU-145	IC₅₀	0.53 μM Compound: 28g, MPC-3100	Cytotoxicity against human DU145 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human DU145 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
HCT-116	IC₅₀	0.06 μM Compound: 28g, MPC-3100	Inhibition of human HSP90 in HCT116 cells expressing Her2 gene assessed as degradation of Her2 after 4 hrs by luciferase reporter gene assay Inhibition of human HSP90 in HCT116 cells expressing Her2 gene assessed as degradation of Her2 after 4 hrs by luciferase reporter gene assay	[PMID: 22913511]
HCT-116	IC₅₀	0.1 μM Compound: 28g, MPC-3100	Inhibition of human HSP90 in HCT116 cells assessed as degradation of Akt incubated for 24 hrs by Western blot method Inhibition of human HSP90 in HCT116 cells assessed as degradation of Akt incubated for 24 hrs by Western blot method	[PMID: 22913511]
HCT-116	IC₅₀	0.1 μM Compound: 28g, MPC-3100	Inhibition of human HSP90 in HCT116 cells assessed as degradation of Her2 incubated for 24 hrs by Western blot method Inhibition of human HSP90 in HCT116 cells assessed as degradation of Her2 incubated for 24 hrs by Western blot method	[PMID: 22913511]
HCT-116	IC₅₀	0.54 μM Compound: 28g, MPC-3100	Cytotoxicity against human HCT116 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human HCT116 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
HT-29	IC₅₀	0.42 μM Compound: 28g, MPC-3100	Cytotoxicity against human HT-29 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human HT-29 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
LNCaP	IC₅₀	0.51 μM Compound: 28g, MPC-3100	Cytotoxicity against human LNCAP cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human LNCAP cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
MV4-11	IC₅₀	0.25 μM Compound: 28g, MPC-3100	Cytotoxicity against human MV4-11 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human MV4-11 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
NCI/ADR-RES	IC₅₀	4.3 μM Compound: 28g, MPC-3100	Cytotoxicity against human NCI-ADR-RES cells overexpressing P-gp 1 assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human NCI-ADR-RES cells overexpressing P-gp 1 assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
NCI-H69	IC₅₀	0.15 μM Compound: 28g, MPC-3100	Cytotoxicity against human NCI-H69 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human NCI-H69 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
NCI-N87	IC₅₀	0.1 μM Compound: 28g, MPC-3100	Inhibition of human HSP90 in NCI-N87 cells assessed as degradation of Her2 incubated for 24 hrs by Western blot method Inhibition of human HSP90 in NCI-N87 cells assessed as degradation of Her2 incubated for 24 hrs by Western blot method	[PMID: 22913511]
NCI-N87	IC₅₀	0.2 μM Compound: 28g, MPC-3100	Cytotoxicity against human NCI-N87 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human NCI-N87 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
OVCAR-8	IC₅₀	0.49 μM Compound: 28g, MPC-3100	Cytotoxicity against human OVCAR8 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human OVCAR8 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 958025-66-6
Appearance Solid
Peso molecular 549.44
Fòrmula C₂₂H₂₅BrN₆O₄S
Color White to off-white
SMILES

NC1=C2C(N(CCC3CCN(C([C@@H](O)C)=O)CC3)C(SC4=C(Br)C=C(OCO5)C5=C4)=N2)=NC=N1
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvente y solubilidad

In Vitro:

DMSO : 5.5 mg/mL (10.01 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8200 mL

9.1002 mL

18.2003 mL

5 mM

0.3640 mL

1.8200 mL

3.6401 mL

10 mM

0.1820 mL

0.9100 mL

1.8200 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (272 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Kim SH, et al. Discovery of (2S)-1-[4-(2-{6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-based Hsp90 inhibitor. J Med Chem. 2012 Sep 13;55(17):7480-501. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8200 mL	9.1002 mL	18.2003 mL	45.5009 mL
	5 mM	0.3640 mL	1.8200 mL	3.6401 mL	9.1002 mL
	10 mM	0.1820 mL	0.9100 mL	1.8200 mL	4.5501 mL

Keywords

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

MPC-3100

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Extracellular Vesicles (EVs) Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Ver todos los productos específicos de isoformas HSP

Actividad biológica

Chemical Information

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

MPC-3100

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Extracellular Vesicles (EVs) Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Ver todos los productos específicos de isoformas HSP

Actividad biológica

Chemical Information

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

MPC-3100 Related Classifications

HY-13301 Related Classifications